U.S. Stock Movement | Cardiovascular pharmaceutical company Braveheart Bio (BRVE.US) has launched in the U.S. stock market, with its stock price rising over 75% after opening.

Zhito Finance APP has learned that on Thursday, cardiovascular pharmaceutical company Braveheart Bio (BRVE.US) made its debut on the US stock market. As of the time of this report, the stock has risen over 75%, trading at $31.405. The IPO price was $18. Founded in 2024, Braveheart Bio is a late-stage biopharmaceutical company focused on developing innovative therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. The company's core candidate drug, BHB-1893 (also known as HRS-1893), is an oral small molecule myosin inhibitor that specifically inhibits cardiac myosin ATPase activity, normalizing myocardial contractility, reducing left ventricular hypertrophy, and improving diastolic compliance. The drug received global (excluding Greater China) exclusive licensing from Jiangsu Hengrui Medicine in September 2025.